Nicotine patches — Competitive Intelligence Brief

Nicotine patches (Nicotine patches) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotinic acetylcholine receptor agonist. Area: Addiction Medicine / Smoking Cessation.

marketed Nicotinic acetylcholine receptor agonist Nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation Small molecule

Target snapshot

Nicotine patches (Nicotine patches) — University of California, San Francisco. Nicotine patches deliver nicotine transdermally to bind nicotinic acetylcholine receptors in the brain, reducing cravings and withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine patches TARGET	Nicotine patches	University of California, San Francisco	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicoderm patch first, then Aveva patch	Nicoderm patch first, then Aveva patch	University of Maryland, Baltimore	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine gum (C)	Nicotine gum (C)	22nd Century Group, Inc.	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Motivation-Phase Nicotine Mini-Lozenge	Motivation-Phase Nicotine Mini-Lozenge	VA Office of Research and Development	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicoderm C-Q Transdermal Product	Nicoderm C-Q Transdermal Product	University of Miami	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicoderm Transdermal Patch	Nicoderm Transdermal Patch	University of Pennsylvania	marketed	Nicotinic receptor agonist	Nicotinic acetylcholine receptors
C-11 labeled nicotine	C-11 labeled nicotine	University of Cincinnati	marketed	PET imaging agent / radiotracer	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotinic acetylcholine receptor agonist class)

1. University of Wisconsin, Madison · 3 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. VA Office of Research and Development · 2 drugs in this class
4. Iowa City Veterans Affairs Medical Center · 1 drug in this class
5. Johns Hopkins University · 1 drug in this class
6. Medical University of Vienna · 1 drug in this class
7. 22nd Century Group, Inc. · 1 drug in this class
8. University of Auckland, New Zealand · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class
10. University of Miami · 1 drug in this class